Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49.9M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
1.62M
-
Shares change
-
+692K
-
Total reported value, excl. options
-
$8.93M
-
Value change
-
+$3.61M
-
Number of buys
-
11
-
Number of sells
-
-12
-
Price
-
$5.52
Significant Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q2 2024
29 filings reported holding TLSI - TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value as of Q2 2024.
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.62M shares
of 49.9M outstanding shares and own 3.24% of the company stock.
Largest 10 shareholders include Duquesne Family Office LLC (427K shares), VANGUARD GROUP INC (416K shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (215K shares), GEODE CAPITAL MANAGEMENT, LLC (138K shares), MILLENNIUM MANAGEMENT LLC (123K shares), Lido Advisors, LLC (44.4K shares), WOLVERINE ASSET MANAGEMENT LLC (43.5K shares), HRT FINANCIAL LP (35.5K shares), Connecticut Wealth Management, LLC (32.9K shares), and BlackRock Inc. (30.3K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.